MediGene AG


    • Company type:
      • Research & Development
    • Year founded:
    • 1994
    • Employees (at the site):
    • 102
    • Turnover range:
    • <5m EUR
    • Products/services:
    • With Eligard® for the treatment of prostate cancer, MediGene is the first German biotech company with a drug on the market. Submission of the New Drug Application for the second drug, Polyphenon® E Ointment for the treatment of genital warts, is scheduled for 2005. Apart from that, several drug candidates are currently undergoing clinical development.

    • Core competencies:
    • MediGene's core competence is research into and development of novel approaches to the treatment of various tumor diseases (oncology). It is MediGene's strategy to integrate all core divisions of a biopharmaceutical company from research and development to commercialization of drugs.

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Preclinical development
      • Biotechnology: Therapeutic drug development
    • Industries NACE:
      • 72.11: Research and experimental development on biotechnology
      • 21.10: Manufacture of basic pharmaceutical products
      • 21.20: Manufacture of pharmaceutical preparations
      • 32.50: Manufacture of medical and dental instruments and supplies
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Peter Llewellyn-Davies (Mr.)
      - Management

      Dr. Frank Mathias (Mr.)
      - Management

      Kerstin Langlotz (Mrs.)
      - Sales / marketing